News

Categories

July 11, 2022

Zymeworks Statement on U.S. Supreme Court Overturning Roe v. Wade

June 27, 2022

Zymeworks Appoints Dr. Paul Moore As Chief Scientific Officer

May 27, 2022

Zymeworks Announces Participation In Upcoming Investor Conference

May 26, 2022

Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022

May 18, 2022

Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI

May 2, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences

April 28, 2022

Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer

April 27, 2022

Zymeworks Announces Presentations At 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting

April 19, 2022

Zymeworks To Host First Quarter 2022 Results Conference Call

April 1, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences

March 3, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences

February 24, 2022

Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results